Dorota Religa, MD, PhD, Karolinska Institutet, Solna, Sweden, discusses the challenges surrounding clinical trials for drugs targeting cognitive decline. While in trials, patients are motivated and committed to diagnosis and treatment, real life presents a different picture. Stigma around cognitive disorders often leads patients to delay seeking medical help. Additionally, individuals may not recognize their own symptoms, relying on family or co-workers to notice changes. This lack of awareness can hinder early diagnosis, which is crucial for effective treatment. Recent studies emphasize the importance of a ‘timely diagnosis’, particularly for older adults, which takes into consideration the preferences and unique circumstances of the individual. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
